Therapy anticipated to decrease chronic kidney disease
The much anticipated listing of sevelamer hydrochloride (Renagel®) on the Pharmaceutical Benefits Scheme (PBS), this month is expected to improve treatment outcomes for chronic kidney disease (CKD) – helping patients reach phosphate targets and decreasing the risk of death from complications of the disease.
Welcoming the PBS listing of Renagel from 1 December 2007, Dr Tim Mathew, medical director of Kidney Health Australia, said the availability of Renagel means that CKD patients on dialysis will now have a real chance to make phosphate targets – an important consideration given that one in two currently have a target serum phosphate level above the recommended target of 0.8–1.60 mmol/L outlined in the CARI Guidelines.
![Dandenong Mayor [left] stands next to aged care resident and aged care staff member](https://agedcareguide-assets.imgix.net/news/articles/wp/belv__2204.jpg?fm=pjpg&w=370)
![Dandenong Mayor [left] stands next to aged care resident and aged care staff member](https://agedcareguide-assets.imgix.net/news/articles/wp/belv__2204.jpg?fm=pjpg&w=520&format=auto&q=65)
